Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Riociguat
Treatment for Pulmonary Arterial Hypertension
Typical Dosage: 0.5mg three times daily, titrated up to 2.5mg three times daily
Effectiveness
82%
Safety Score
35%
Clinical Trials
47
Participants
2.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
0.5mg three times daily, titrated up to 2.5mg three times daily
Time to Effect
1-3 months
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$120,000
Monitoring:$5,000
Side Effect Mgmt:$1,000
Total Annual:$126,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$160,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$360,000
Cost per Remission
$2,520,000
Riociguat Outcomes
for Pulmonary Arterial Hypertension
Efficacy Outcomes
Overall Effectiveness
+82%
Response Rate
+35%
Remission Rate
+5%
Common Side Effects
Headache
+25%
Dyspepsia
+12%
Dizziness
+10%
Nausea
+10%
Hypotension
+7%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
4 active trials recruiting for Riociguat in Pulmonary Arterial Hypertension
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
NCT04062565RECRUITINGPHASE3
20 participants
INTERVENTIONAL
Tucson, United States
Started: Mar 25, 2019
Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
NCT02562235ACTIVE NOT RECRUITINGPHASE3
24 participants
INTERVENTIONAL
Cali, Colombia +15 more
Started: Oct 29, 2015
Riociguat in Triple Therapy for Pulmonary Arterial Hypertension in Real-World Practice
NCT07374302NOT YET RECRUITING
15 participants
OBSERVATIONAL
Started: Mar 1, 2026
Pulmonary Hypertension: Intensification and Personalisation of Combination Rx
NCT05825417RECRUITINGPHASE4
40 participants
INTERVENTIONAL
Sheffield, United Kingdom
Started: Jun 14, 2023
Completed Clinical Trials
13 completed trials for Riociguat in Pulmonary Arterial Hypertension
A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)
NCT04813926COMPLETED
500 participants
OBSERVATIONAL
Phoenix, United States +49 more
Started: Jul 16, 2021
Bioequivalence Study of Riociguat 2.5 mg Film Coated Tablets and Adempas (Riociguat) 2.5 mg Film Coated Tablets
NCT06180096COMPLETEDPHASE1
36 participants
INTERVENTIONAL
Ahmedabad, India
Started: Mar 7, 2023
Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
NCT02891850COMPLETEDPHASE4
225 participants
INTERVENTIONAL
Phoenix, United States +80 more
Started: Jan 11, 2017
Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)
NCT02428985COMPLETED
882 participants
OBSERVATIONAL
Multiple Locations, Japan
Started: Jun 29, 2015
BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
NCT00863681COMPLETEDPHASE3
396 participants
INTERVENTIONAL
Los Angeles, United States +98 more
Started: Mar 12, 2009
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
NCT00810693COMPLETEDPHASE3
445 participants
INTERVENTIONAL
Tucson, United States +121 more
Started: Dec 17, 2008
Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)
NCT02191137COMPLETEDPHASE4
75 participants
INTERVENTIONAL
Tucson, United States +58 more
Started: Sep 23, 2014
A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
NCT02759419COMPLETEDPHASE4
18 participants
INTERVENTIONAL
Besançon, France +8 more
Started: Jun 16, 2016
A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
NCT02545465COMPLETED
125 participants
OBSERVATIONAL
Many Locations, Belgium +6 more
Started: Sep 15, 2015
Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude
NCT02024386COMPLETEDPHASE4
28 participants
INTERVENTIONAL
Durham, United States
Started: Jan 1, 2014
Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor
NCT02007629COMPLETEDPHASE3
61 participants
INTERVENTIONAL
La Jolla, United States +26 more
Started: Feb 18, 2014
An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension
NCT00454558COMPLETEDPHASE2
75 participants
INTERVENTIONAL
Heidelberg, Germany +14 more
Started: Jan 1, 2007
Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )
NCT02117791COMPLETED
1.3K participants
OBSERVATIONAL
Multiple Locations, Japan
Started: Jul 16, 2014
Showing 20 of 49 total trials